Navigation Links
New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure
Date:10/2/2009

TEL-AVIV, Israel and PORTLAND, Oregon, October 2 /PRNewswire/ --

- Bioreactance-based Noninvasive Measurements During Exertion Identified Abnormalities of Cardiovascular Function and Might be Useful for Indexing Disease Severity, Prognostication, and for Tracking Responses to Treatment in Clinical Practice and Trials

Results from a multicenter study of Cheetah Medical's Exercise Cardiac Output (ECO(R)) stress test protocol for chronic heart failure were published earlier this month in the Journal of Cardiac Failure, the official journal of the Heart Failure Society of America and the Japanese Heart Failure Society. With approximately 6 million Americans diagnosed with heart failure, it is a leading cause of morbidity and mortality. After heart failure is diagnosed, the 1-year mortality rate is high, with 1in 5 dying. Eighty percent of men and 70% of women 65 years of age who have heart failure will die within 8 years, and one in 8 US deaths has HF mentioned on the death certificate. Unfortunately, heart failure specialists have limited tools with which to monitor heart failure progression, determine prognosis and response to treatment. Recently, it was shown that peak Cardiac Output and Peak Cardiac Power Output are the strongest predictors of heart failure severity, however access to these current methods is limited to a minute portion of heart failure patients due to cost and complexity of the devices.

In this study, Cheetah Medical's NICOM(R) System was used to continuously monitor the Cardiac Output response during exercise stress testing as well as Cardiac Power Output and a host of other hemodynamic parameters in patients with varying degrees of chronic heart failure and compared to the traditional method of measuring oxygen consumption which are obtained from analysis of expired gases. The results from both methods correlated extremely well, demonstrating the potential to use the NICOM system to routinely monitor heart failure patients without the significant limitations of expired breath gas technologies.

Matthew Maurer MD, Director of the Clinical Cardiovascular Research Laboratory for the Elderly, Associate Professor of Clinical Medicine at Columbia University Medical Center and the study's Primary Investigator, said: "We continually search for practical means of assessing the status of our heart failure patients that are useful both for routine clinical practice and for clinical research. Although the usefulness of measuring oxygen consumption is well established, these data suggest that additional physiologic and prognostic information can be obtained using the NICOM, which is as easy to measure as an electrocardiogram and does not require special training for its interpretation."

Daniel Burkhoff, M.D., Ph.D., Medical Director of Cheetah Medical, an Adjunct Associate Professor of Medicine at Columbia University Medical School and a leading clinical researcher in the field of heart failure added, "With the results of this study showing good correlations to oxygen consumption and several prior independent studies showing that peak cardiac power can be even more predictive of outcomes, we are encouraged that we will see these measurements used more often in a variety of settings. Currently, the NICOM appears to offer the simplest solution for clinicians to measure cardiac output and power during exercise. We are planning a large multicenter study to confirm the prior smaller studies to prove the utility of peak cardiac power for predicting the risks of hospitalizations, the need for heart transplant, left ventricular assist devices and mortality."

About Cheetah Medical

Cheetah Medical delivers accurate noninvasive cardiac output (CO), noninvasive blood pressure (NIBP), stroke volume variation (SVV), total peripheral resistance (TPR) and other vital hemodynamic monitoring parameters to provide continuous, clinically actionable information for fluid and drug optimization in acute and ambulatory care settings, including intensive care, emergency, perioperative care, dialysis and outpatient cardiology. The NICOM(R) Noninvasive Cardiac Output & Hemodynamic Monitoring System uses Cheetah Medical's proprietary BIOREACTANCE(R) Technology, which has validated performance accuracy and faster directional changes compared to invasive CO measurement methods, with less potential costs and risks. Cheetah Medical worldwide headquarters are located in Tel-Aviv, Israel and its United States headquarters are located in Portland, Oregon. For more information, visit our website at http://www.cheetah-medical.com.

    For More Information Contact:

    Yoav Avidor, MD
    Chief Executive Officer
    Cheetah Medical
    yoav@cheetah-medical.com
    Telephone: +972-3-644-0288

SOURCE Cheetah Medical Ltd


'/>"/>
SOURCE Cheetah Medical Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
3. Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
4. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
5. EPA announces research strategy to study nanomaterials
6. Leading Biotechnology Company Awards Phase III Cardiac Safety Study to iCardiac
7. PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
8. Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
9. Medication Telemonitoring Improves Compliance and Behavior in NIH Study
10. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
11. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per share will be ... record as of the close of business on June 24, ... the Board of Directors and may be adjusted as business ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... There is no saying when ... relentless pressures in pricing and lack in consumer confidence. ... though - numerous opportunities are up for grabs but ... presents four names in this sector: Portola Pharmaceuticals Inc. ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:3/11/2016)... March 11, 2016 --> ... research report "Image Recognition Market by Technology (Pattern Recognition), ... Advertising), by Deployment Type (On-Premises and Cloud), by Industry ... published by MarketsandMarkets, the global market is expected to ... 29.98 Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... -- Nigeria . Recently, the ... public service employees either did not exist with their ...    --> Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> DERMALOG, the biometrics innovation ...
Breaking Biology News(10 mins):